These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 21859266)

  • 1. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program.
    Richeldi L; du Bois RM
    Expert Rev Respir Med; 2011 Aug; 5(4):473-81. PubMed ID: 21859266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
    Azuma A
    Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
    Costabel U
    Eur Respir Rev; 2011 Sep; 20(121):201-7. PubMed ID: 21881148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
    Taniguchi H; Kondoh Y; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sato A; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Res; 2011 Jul; 12(1):93. PubMed ID: 21756364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
    Potts J; Yogaratnam D
    Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis].
    Bonella F; Wessendorf TE; Costabel U
    Dtsch Med Wochenschr; 2013 Mar; 138(11):518-23. PubMed ID: 23423955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone in idiopathic pulmonary fibrosis.
    Maher TM
    Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
    Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
    Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.
    Raghu G
    Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Serrano-Mollar A; Ancochea J
    Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone: an update on clinical trial data and insights from everyday practice.
    Kreuter M
    Eur Respir Rev; 2014 Mar; 23(131):111-7. PubMed ID: 24591668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.